• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Atezolizumab for the treatment of colorectal cancer: the latest evidence and clinical potential
【24h】

Atezolizumab for the treatment of colorectal cancer: the latest evidence and clinical potential

机译：atezolizumab用于治疗结直肠癌：最新的证据和临床潜力

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Atezolizumab is a fully humanized, engineered monoclonal antibody that specifically targets PD-L1, key molecule in the cancer-immunity pathway. Atezolizumab is currently approved for the treatment of metastatic non-small-cell lung cancer and advanced urothelial carcinomas. Areas covered: In this review, we will present the available data supporting the efficacy of atezolizumab for the treatment of metastatic colorectal cancer (mCRC). We will also provide an update on the ongoing/future clinical trials evaluating the role of atezolizumab for the treatment of CRC in different settings (alone or in combination with other checkpoint inhibitors and/or targeted therapies). So far, a small subgroup of mCRC (those with deficiency in mismatch repair - dMMR) appears to benefit significantly from checkpoint inhibitors. As expected, further research is needed to develop biomarkers, effective therapeutic strategies and novel combinations to overcome immune escape resistance and achieve better responses with minimal toxicities. Expert opinion: Interim analyses from ongoing early-phase studies in mCRC have shown encouraging activity of atezolizumab in combination with chemotherapy and/or targeted therapies, especially with MEK inhibitor cobimetinib. Within the next few years, this PD-L1 checkpoint inhibitor will likely be included as one of the treatment options for CRC, at least for patients with dMMR.
机译：简介：atezolizumab是一种完全人性化的工程单克隆抗体，其特异性靶向PD-L1，癌症免疫途径中的关键分子。目前批准atezolizumab用于治疗转移性非小细胞肺癌和晚期尿路上皮癌。所涵盖的区域：在本综述中，我们将介绍支持atezolizumab治疗转移性结肠直肠癌（MCRC）疗效的可用数据。我们还将在持续/未来的临床试验中提供更新，评估atezolizumab在不同的环境中治疗CRC的作用（单独或与其他检查点抑制剂和/或靶向治疗组合）。到目前为止，MCRC的一个小亚组（不匹配修复缺乏缺乏症 - DMMR）似乎从检查点抑制剂显着受益。正如预期的那样，需要进一步的研究来开发生物标志物，有效的治疗策略和新组合，以克服免疫逃生抗性，并达到最低毒性的更好反应。专家意见：来自MCRC中正在进行的早期研究的临时分析表明，艾司唑妥昔单抗与化疗和/或靶向疗法组合的令人鼓舞的活动，特别是MEK抑制剂Cobimetinib。在未来几年内，该PD-L1检查点抑制剂可能被包括作为CRC的一种治疗方案之一，至少对于DMMR的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号